全讯白菜网(600cc·安全认证)官方网站-Made in China

师资队伍

教授副教授全体师资

副教授

首页

师资队伍

副教授

吕梦迪

职称：副教授

联系电话：--

email：mengdilv@ahmu.edu.cn

研究方向：1.新型金属免疫药物的设计及抗肿瘤性能研究2.诊疗一体化金属先导化合物的构筑及生物应用研究

个人简历科研项目论文专著专利与技术许可荣誉与奖励

吕梦迪，博士，600cc全讯白菜网校聘副教授，硕士生导师。迄今在Angewandte Chemie International Edition；National Science Review；Small；Journal of Medicinal Chemistry等国际核心期刊上发表SCI论文10余篇。参与多项国家自然科学基金及企业合作项目。

学习和工作经历

2024.08-至今 600cc全讯白菜网校聘副教授

2018.09-2023.12 南京师范大学化学与材料科学学院博士

2014.09-2018.06 安庆师范大学化学化工学院学士

1. Lv Mengdi, Zheng Yue, Wu Jian, Shen Zhengqi, Guo Binglian, Hu Guojing, Huang Yuanlei, Zhao Jingyue, Qian Yong, Su Zhi, Wu Chao*, Xue Xuling*, Liu Hong-Ke*, Mao Zong-Wan*. Evoking ferroptosis by synergistic enhancement of a cyclopentadienyl iridium-betulin immune agonist. Angew. Chem. Int. Ed. 2023, 62, e202312897. (第一作者, IF: 16.1, Top期刊, 中科院一区)

2. Lv Mengdi, Zheng Yue, Dai Xiangyu, Zhao Jingyue, Hu Guojing, Ren Meng, Shen Zhengqi, Su Zhi, Wu Chao*, Liu Hong-Ke*, Xue Xuling*, Mao Zong-Wan*. Ruthenium(Ⅱ)-arene complex triggers immunogenic ferroptosis for reversing drug resistance. J. Med. Chem. 2024, 67, 20156-20171. (第一作者, IF: 6.8, Top期刊, 中科院一区)

3. Lv Mengdi, Qian Xiaoting, Li Shijie, Gong Jie, Wang Qun, Qian Yong, Su Zhi, Xue Xuling*, Liu Hong-Ke*. Unlocking the potential of iridium and ruthenium arene complexes as anti-tumor and anti-metastasis chemotherapeutic agents. J. Inorg. Biochem. 2023, 238, 112057. (第一作者, IF: 3.9, 中科院二区)

4. Hu Guojing, Lv Mengdi, Guo Binglian, Huang Yuanlei, Su Zhi, Qian Yong, Xue Xuling*, Liu Hong-Ke*. Immunostimulation with chemotherapy of a ruthenium-arene complex via blockading CD47 signal in chronic myelogenous leukemia cells. J. Inorg. Biochem. 2023, 243, 112195. (共同第一作者, IF: 3.8, 中科院二区)

5. Zhang Juyang, Lv Mengdi, Wang Xinye, Wu Fan, Yao Cheng, Shen Jian, Zhou Ninglin*, Sun Baohong*. An immunomodulatory biomimetic single-atomic nanozyme for biofilm wound healing management. Small 2023, 19, 2302587. (共同第一作者, IF: 13.0, Top期刊, 中科院二区)

6. Su Yutian, Lv Mengdi, Huang Zheng, An Nannan, Chen Yi, Wang Haoru, Li Zhengtu, Wu Shishan*, Ye Feng*, Shen Jian*, Li Ao*. Defect engineering to tailor structure-activity relationship in biodegradable nanozymes for tumor therapy by dual-channel death strategies. J. Control. Release 2024, 367, 557-571.

7. Huang Yuanlei, Lv Mengdi, Guo Binglian, Hu Guojing, Qian Yong, Su Zhi, Xue Xuling*, Liu Hong-Ke*. Selectively attacking tumor cells of Ru/Ir–arene complexes based on meclofenamic acid via cyclooxygenase-2 inhibition. Dalton Trans. 2023, 52, 6922-6933.

8. Qian Xiaoting, Lv Mengdi, Wang Qun, Tao Qin, Xue Xuling*, Liu Hong-Ke*. Synthesis and antitumor properties of 3-(2-pyridine-3-vinyl)-1H-indole dipyridine ruthenium complex. Chinese J. Inorg. Chem. 2021, 37, 824-834.

9. Zhao Jingyue, Dai Xiangyu, Lv Mengdi, Liu Hanxue, Ren Meng, Hu Guojing, Xue Xuling*, Liu Hong-Ke*. An efficient ICD inducer based on Ir(Ⅲ) cyclometalated complex for anticancer and anti-migration effects towards cisplatin-resistant cancer cells. Inorg. Chim. Acta 2025, 580, 122601.

10. Xue Xuling, Qian Chenggen, Tao Qin, Dai Yuanxin, Lv Mengdi, Dong Jingwen, Su Zhi, Qian Yong, Zhao Jing*, Liu Hong-Ke*, Guo Zijian*. Using bio-orthogonally catalyzed lethality strategy to generate mitochondria-targeting anti-tumor metallodrugs in vitro and in vivo. Natl. Sci. Rev. 2021, 8, nwaa286.